Eiger BioPharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch EIGR and buy or sell other stocks, ETFs, and their options commission-free!About EIGR
Eiger BioPharmaceuticals, Inc. operates as a biopharmaceutical company, which focuses on the development of innovative therapies for rare metabolic diseases. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia.
CEODavid Apelian, MD, PhD
CEODavid Apelian, MD, PhD
Employees—
Employees—
HeadquartersPalo Alto, California
HeadquartersPalo Alto, California
Founded2008
Founded2008
Employees—
Employees—
EIGR Key Statistics
Market cap12.59M
Market cap12.59M
Price-Earnings ratio-0.17
Price-Earnings ratio-0.17
Dividend yield—
Dividend yield—
Average volume507.40
Average volume507.40
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$16.00
52 Week high$16.00
52 Week low$1.10
52 Week low$1.10
Stock Snapshot
As of today, Eiger BioPharmaceuticals(EIGR) shares are valued at $8.50. The company's market cap stands at 12.59M, with a P/E ratio of -0.17.
During the trading day, Eiger BioPharmaceuticals(EIGR) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading volume for Eiger BioPharmaceuticals(EIGR) stock has reached 0, versus its average volume of 507.4.
Over the past 52 weeks, Eiger BioPharmaceuticals(EIGR) stock has traded between a high of $16.00 and a low of $1.10.
Over the past 52 weeks, Eiger BioPharmaceuticals(EIGR) stock has traded between a high of $16.00 and a low of $1.10.
People also own
Based on the portfolios of people who own EIGR. This list is generated using Robinhood data, and it’s not a recommendation.